Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases

Cellular and Molecular Life Sciences

Volumn 58, Issue 9, 2001, Pages 1333-1339

  Kotala, V ^a   Uldrijan, S ^a   Horky, M ^a   Trbusek, M ^b   Strnad, M ^c   Vojtesek, B ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b Research Institute of Child Health Brno   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

p21; p53; Roscovitine; Transcriptional activity; Tumour cells

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P53; ROSCOVITINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CELL PROLIFERATION; DRUG USE; HUMAN; HUMAN CELL; TRANSCRIPTION REGULATION; TUMOR;

EID: 0034848953     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000944     Document Type: Article

References (48)

1. The complexity of p53 modulation: Emerging patterns from divergent signals
2. Covalent and noncovalent modifiers of the p53 protein
3. Multisite phosphorylation and the integration of stress signals at p53
4. DNA damage activates p53 through a phosphorylation-acetylation cascade
5. WAF1, a potential mediator of p53 tumor suppression
6. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest
7. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis
8. A p53-independent pathway for induction of p21waf1cip1 and concomitant G1 arrest in UV-irradiated human skin fibroblasts
9. p53, the cellular gatekeeper for growth and division
10. Somatic point mutations in the p53 gene of human tumors and cell lines: Updated compilation
11. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
12. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclindependent kinases
13. p21 is a universal inhibitor of cyclin kinases
14. Inhibition of cyclin-dependent kinases by purine analogues
15. Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds
16. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5
17. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with roscovitine
18. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity
19. Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines
20. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells
21. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity
22. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication
23. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases
24. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases
25. Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription
26. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells
27. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes
28. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53
29. A functional screen for germ line p53 mutations based on transcriptional activation
30. Assay for β-galactosidase in extracts of mammalian cells
31. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53
32. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression
33. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein
34. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies
35. Precise characterisation of monoclonal antibodies to the C-terminal region of p53 protein using the PEPSCAN ELISA technique and a new nonradioactive gel shift assay
36. Monoclonal antibodies specific for simian virus 40 tumor antigens
37. Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues
38. Transcriptional repression by the C-terminal domain of p53
39. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2
40. Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways
41. Discordance between accumulated p53 protein level and its transcriptional activity in response to u.v. radiation
42. From the Cover: p53 accumulates but is functionally impaired when DNA synthesis is blocked
43. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers
44. Sequence-specific transcriptional activation is essential for growth suppression by p53
45. Effects of cyclin-dependent kinase inhibitors on transcription and ocular circadian rhythm of Aplysia
46. Suramin increases p53 protein levels but does not activate the p53-dependent G1 checkpoint
47. Cellular response to DNA damage from a potent carcinogen involves stabilization of p53 without induction of p21(waf1/cip1)
48. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage